Pathogenicity is also a surrogate for effectiveness.
This article forms part of this challenging question.
Histamine triphosphate (H3) is a lung-survivor drug that has been used in the treatment of infectious diseases for a long time but it had not been considered as a therapeutic element in lung cancer.
This indicates that the excretion of estrogen signals is diminished in lung cancer and complements the existing evidence that estrogen drives proliferation in many forms of cancer cell type.
This is why the aim of this review is to develop guidelines for therapeutic development of this drug in select metastatic tumors to a particular degree.

Continue reading